Transgene's Fiscal Vision for 2025
Transgene, a pioneering biotech firm on the Euronext Paris under ticker TNG, is thrilled to announce its financial reporting dates for the upcoming year. This transparency will assist investors and stakeholders in anticipating its pivotal updates.
Key Financial Reporting Dates
As part of its commitment to keeping the market informed, Transgene will unveil important financial reports throughout the year. Mark your calendars for these significant dates:
March 27, 2025: This date will see the release of the 2024 Fiscal Year Results, offering an overview of the company's achievements and financial health from the previous year.
April 24, 2025: The First Quarter 2025 Financial Results will shed light on the company's initial performance metrics for the year.
May 15, 2025: During this period, Transgene will hold its Annual Shareholders' Meeting, engaging directly with investors to discuss the firm's future strategies.
September 16, 2025: This date is set for the announcement of the First Half 2025 Financial Results, further providing stakeholders insights into the company's mid-year performance.
November 4, 2025: Mark your calendars again as this day brings the Third Quarter 2025 Financial Results, concluding the financial reporting cycle for the year.
About Transgene
Transgene is dedicated to the advancement of targeted immunotherapies that leverage viral vector technologies. With a focus on enhancing treatment options for cancer, the company is pioneering several innovative approaches to destruction of cancer cells, both directly and indirectly.
Some of the notable candidates in its clinical pipeline include TG4050, an individualized therapeutic vaccine developed via the myvac® platform, and TG4001, aimed at HPV-positive cancers. Additionally, oncolytic viruses such as BT-001 and TG6050 are under development, showcasing the potential for Transgene’s therapeutic innovations.
The myvac® platform underscores Transgene's commitment to precision medicine by crafting personalized immunotherapy solutions tailored to the unique mutations present in each patient. This program not only employs advanced AI technology through a partnership with NEC but also reflects the company’s dedication to pushing the boundaries of existing cancer treatments.
Furthermore, Transgene's proprietary Invir.IO® platform aims to create a sophisticated new generation of functional oncolytic viruses, enhancing its arsenal against cancer through innovative technology and design.
Staying Connected
For those interested in keeping track of Transgene’s latest updates, additional resources can be found on their official site. The company also encourages investors and interested parties to follow Transgene on social media platforms like X and LinkedIn for real-time updates and insights.
Company Contacts
For inquiries, please reach out to Transgene's media relations:
Caroline Tosch - Corporate Communication Manager
Phone: +33 (0)3 68 33 27 38
Email: communication@transgene.fr
Lucie Larguier - Chief Financial Officer
Email: investorrelations@transgene.fr
Frequently Asked Questions
What is the purpose of Transgene's financial reporting dates?
Transgene's financial reporting dates are aimed at keeping investors and stakeholders informed about the company’s financial performance and future strategies.
How does Transgene utilize viral vector technology?
Transgene employs viral vector technology to create innovative immunotherapies that directly or indirectly target and kill cancer cells.
What notable therapies is Transgene currently developing?
Transgene is developing several therapies, including TG4050, TG4001, BT-001, and TG6050, focusing on individualized treatment options for cancer.
What is the myvac® platform?
The myvac® platform allows the creation of personalized therapeutic vaccines that are tailored to individual patients based on their specific cancer mutations.
How can I stay updated with Transgene's announcements?
You can visit Transgene’s official website and follow their social media accounts for real-time updates on their developments.
